8-K: ADC Therapeutics and Redmile Group Reach Agreement on Preemptive and Advance Subscription Rights

ADC Therapeutics has entered into an agreement with Redmile Group regarding preemptive and advance subscription rights, clarifying the conditions under which Redmile's rights can be restricted.

Summary

• ADC Therapeutics has entered into an agreement with Redmile Group, LLC concerning preemptive and advance subscription rights related to the company's shares.
• The agreement stipulates that ADC Therapeutics' board will not restrict Redmile's preemptive or advance subscription rights unless Redmile's ownership exceeds 20% of the share capital and the board determines Redmile intends to effect a change of control.
• If Redmile's ownership exceeds 20%, the board will provide Redmile an opportunity to explain its intentions before potentially restricting these rights.
• The agreement terminates under several conditions, including the removal of certain articles from the company's articles of association, Redmile's ownership falling below 20% after five years, the company becoming incorporated in the US, Redmile's ownership exceeding 30%, or the board determining Redmile intends to effect a change of control.
• Redmile currently controls approximately 18.93% of the company's share capital.

Sentiment

Score: 7

Explanation: The agreement provides clarity and structure to the relationship between ADC Therapeutics and Redmile, which is generally positive. However, the potential for restrictions on Redmile's rights introduces a slight element of caution.

Positives

• The agreement provides clarity on the conditions under which Redmile's preemptive and advance subscription rights can be restricted.
• The agreement establishes a process for the board to assess Redmile's intentions if their ownership exceeds 20%, ensuring a fair process.
• The agreement allows Redmile to maintain its rights as long as it does not intend to take control of the company.

Negatives

• The agreement allows the board to restrict Redmile's rights if they exceed 20% ownership and are deemed to be attempting a change of control.
• The agreement could potentially limit Redmile's ability to increase its stake in the company beyond 30%.

Risks

• There is a risk that the board could determine Redmile intends to effect a change of control, leading to the restriction of their rights.
• The agreement could be terminated if Redmile's ownership exceeds 30%, potentially impacting their investment.
• The agreement could be terminated if the company is redomiciled to the US, which could have unforeseen consequences.

Future Outlook

The agreement outlines the conditions under which Redmile's preemptive and advance subscription rights will be maintained or restricted, providing a framework for future interactions between the company and Redmile.

Management Comments

• Redmile has confirmed to the Company that, as of the date hereof, it currently has no intention of effecting a change of control of the Company.

Industry Context

This agreement is specific to ADC Therapeutics and Redmile Group, and it addresses the specific articles of association of the company. It is not necessarily indicative of broader industry trends but reflects the need for companies to manage shareholder rights and potential change of control scenarios.

Comparison to Industry Standards

• The agreement is tailored to the specific circumstances of ADC Therapeutics and Redmile Group, making direct comparisons to industry standards difficult.
• Similar agreements are common in situations where a significant shareholder holds a substantial stake in a company, particularly when there are concerns about potential change of control.
• The 20% and 30% thresholds for triggering restrictions on preemptive and advance subscription rights are not uncommon in such agreements.

Stakeholder Impact

• Shareholders will benefit from the clarity provided by the agreement regarding Redmile's rights.
• The agreement could impact Redmile's ability to increase its stake in the company.
• The agreement could impact the company's ability to raise capital in the future.

Next Steps

• ADC Therapeutics will monitor Redmile's shareholding and assess their intentions if their ownership exceeds 20%.
• Redmile will notify the company if their ownership exceeds 20% or 30%.

Key Dates

Keywords

preemptive rights, advance subscription rights, Redmile Group, share capital, change of control, ADC Therapeutics, shareholder rights, corporate governance